Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Compass Therapeutics Q2 EPS $(0.14) Misses $(0.12) Estimate

Author: Benzinga Newsdesk | August 11, 2025 06:03am
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 13.82 percent. This is a 40 percent decrease over losses of $(0.10) per share from the same period last year.

Posted In: CMPX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist